The FDA released their decision almost a month early and approved the new gene therapy Luxturna. The article says pricing should be announced in January, but analysts are speculating a $1million tag.

Edit: As I understand it, the new drug will directly benefit those with an inherited retinal disease caused by defective copies of both RPE65 genes (one defective gene from each parent). The drug, Luxturna, will become commercially available in 2018, and pricing should be announced in Jan.

If the drug is marketed successfully, more companies will be willing to invest $$ towards research for vision disorders caused by other genes. :)

Also it’s been a while since I read through their clinical testing results, but I believe they were extremely positive (almost everyone showed some improvement, significant increase in mobility, and the improvements have been lasting)